JASPER THERAPEUTICS INC

Company Overview

Jasper Therapeutics Inc. is a clinical-stage biotechnology company in the Healthcare sector and Biotechnology industry, focused almost entirely on briquilimab, a monoclonal antibody targeting the SCF/KIT pathway to deplete mast cells. Its lead programs are in mast cell-driven diseases, especially chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, with earlier work in transplant conditioning and other indications largely discontinued. The company has reported encouraging early clinical activity, but it remains pre-commercial, with no product revenue and heavy dependence on clinical trial execution, regulatory progress, and external financing. Jasper also relies on third-party manufacturers and has a small operational footprint, which makes supply chain and cGMP compliance especially important.

Executive Compensation Practices

For a company like Jasper, executive compensation is typically structured to reward clinical and regulatory milestones rather than commercial sales, since it has no marketed product yet. In the Biotechnology industry, pay often emphasizes equity awards, option grants, and performance-based incentives tied to trial readouts, enrollment progress, IND/Phase advancement, safety outcomes, and financing execution. Jasper’s recent focus on CSU/CIndU, restructuring, and cash preservation suggests compensation decisions may also be influenced by runway extension, headcount reductions, and successful capital raising. Because the company faces going-concern pressure and ongoing losses, boards in this sector often use long-term equity to align management with dilution-sensitive shareholders and to retain talent through volatile development cycles.

Insider Trading Considerations

Insider trading patterns at Jasper should be viewed in the context of a small clinical-stage biotech with highly binary news flow. Trading activity can be especially sensitive around trial updates, investigation outcomes, financing events, and regulatory decisions, since these can materially move the stock and change the company’s funding outlook. The July 2025 data anomaly investigation in BEACON, the pause/discontinuation of certain programs, and the September financing are all the kinds of events that can affect insider behavior and trading windows. Because management relies on third-party manufacturing and has explicit going-concern risk, insiders may be subject to heightened trading restrictions and may avoid transactions near data releases, financing announcements, or discussions with potential partners.